Trial Profile
Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anti-tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone acetate; Enzalutamide; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PRIMCAB
- Sponsors Sanofi
- 19 Jun 2019 Status changed from completed to discontinued.
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 19 Jan 2018 Planned End Date changed from 15 Feb 2018 to 15 May 2018.